...A. Highlights: Saw continued sequential QoverQ recovery in financial performance from revenue and margin dip experienced in 1H20, due to pandemic and its economic repercussions. 1. Revenues were above prior year levels on reported basis and essentially flat organically vs. 4Q19. a. b. Non-GAAP GM, operating margin, EPS and free cash flow, all exceeded 4Q19 levels. 2. Over course of 2020, stepped up investments and made significant progress in three areas of substantial long-term growth potential; proteomics, spatial and single-cell biology and molecular viral diagnostics. a. Initiated further operational excellence programs for productivity improvements, including restructurings in NANO Group and Invest, and for capacity expansion, particularly in BioSpin and CALID groups. B. 4Q20 Results: Pleased with continued sequential recovery in 4Q20. 1. 2. Revenues $627.5m. Rose $28m or 4.6% YoverY, including favorable foreign currency translation of $27m or 4.6%. a. b. On organic basis, revenues...
